Search research articles
Contact Us
Filters
Showing results (61-70 of 120) with videos related to
Page
of 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 16, 2020
The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Maximilian Linxweiler, Fengshen Kuo, Nora Katabi, et al.
Head & Neck
|
October 21, 2025
Proton Therapy for Paranasal Sinus Cancer: Clinical Outcomes and Patterns of Failure
Caineng Cao, Teeradon Treechairusame, Nadeem Riaz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 1, 2013
A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer
Matthew G Fury, Nancy Y Lee, Eric Sherman, et al.
Lancet Regional Health. Americas
|
January 19, 2026
Intensity-modulated proton therapy vs intensity-modulated radiotherapy in nasopharyngeal carcinoma: a case-control study
Caineng Cao, Teeradon Treechairusame, Amir H Safavi, et al.
Ophthalmology
|
July 16, 2017
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy
Jasmine H Francis, Larissa A Habib, David H Abramson, et al.
EJNMMI Research
|
October 8, 2024
[<sup>18</sup>F]TFB PET/CT misses intense [<sup>124</sup>I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer
Philipp Backhaus, Keith S Pentlow, Alan L Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404)
Alan L Ho, Nathan R Foster, Alex J Zoroufy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
The Journal of Clinical Investigation
|
September 27, 2016
Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine
James Nagarajah, Mina Le, Jeffrey A Knauf, et al.
Molecular Cancer Research : MCR
|
October 12, 2021
Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy
Mark Lee, Brian R Untch, Bin Xu, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 120) with videos related to
Sort By:
Page
of 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 16, 2020
The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Maximilian Linxweiler, Fengshen Kuo, Nora Katabi, et al.
Head & Neck
|
October 21, 2025
Proton Therapy for Paranasal Sinus Cancer: Clinical Outcomes and Patterns of Failure
Caineng Cao, Teeradon Treechairusame, Nadeem Riaz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 1, 2013
A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer
Matthew G Fury, Nancy Y Lee, Eric Sherman, et al.
Lancet Regional Health. Americas
|
January 19, 2026
Intensity-modulated proton therapy vs intensity-modulated radiotherapy in nasopharyngeal carcinoma: a case-control study
Caineng Cao, Teeradon Treechairusame, Amir H Safavi, et al.
Ophthalmology
|
July 16, 2017
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy
Jasmine H Francis, Larissa A Habib, David H Abramson, et al.
EJNMMI Research
|
October 8, 2024
[<sup>18</sup>F]TFB PET/CT misses intense [<sup>124</sup>I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer
Philipp Backhaus, Keith S Pentlow, Alan L Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404)
Alan L Ho, Nathan R Foster, Alex J Zoroufy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
The Journal of Clinical Investigation
|
September 27, 2016
Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine
James Nagarajah, Mina Le, Jeffrey A Knauf, et al.
Molecular Cancer Research : MCR
|
October 12, 2021
Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy
Mark Lee, Brian R Untch, Bin Xu, et al.
Page
of 12